Dare Bioscience announced the publication of positive Phase 1 clinical study results for its topical sildenafil cream (DARE-VVA1) in healthy postmenopausal women, showing it was well-tolerated with minimal systemic exposure. This publication reinforces the potential of their product for female sexual arousal disorder and supports their strategy for future FDA approval, potentially strengthening their competitive position in women's health.
Dare Bioscience (DARE) has announced the publication of Phase 1 clinical study results for its proprietary Sildenafil Cream, 3.6%, in a peer-reviewed journal. The study demonstrated that the cream was well-tolerated in postmenopausal women with minimal systemic exposure, supporting its potential as a localized treatment for female sexual arousal disorder. This is a positive development for DARE as it validates their product's safety profile and mechanism of action, which is crucial for advancing towards FDA approval via the 505(b)(2) pathway. While not a direct market-moving event like an FDA approval, it provides scientific credibility and could attract investor interest in the long term, as it addresses a significant unmet medical need in women's health. Short-term impact might be moderate, but long-term, it strengthens DARE's pipeline and competitive position.